Mitchell P. Levesque

1.9k total citations
26 papers, 325 citations indexed

About

Mitchell P. Levesque is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Mitchell P. Levesque has authored 26 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 8 papers in Oncology and 8 papers in Immunology. Recurrent topics in Mitchell P. Levesque's work include Melanoma and MAPK Pathways (7 papers), Immunotherapy and Immune Responses (4 papers) and Nonmelanoma Skin Cancer Studies (4 papers). Mitchell P. Levesque is often cited by papers focused on Melanoma and MAPK Pathways (7 papers), Immunotherapy and Immune Responses (4 papers) and Nonmelanoma Skin Cancer Studies (4 papers). Mitchell P. Levesque collaborates with scholars based in Switzerland, United States and Germany. Mitchell P. Levesque's co-authors include Reinhard Dummer, Phil F. Cheng, Maria B. Karpova, Joanna Mangana, Sandra N. Freiberger, Daniela Mihic‐Probst, Marieke I.G. Raaijmakers, Daniel Widmer, Apurva Narechania and Ossia M. Eichhoff and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Bioinformatics.

In The Last Decade

Mitchell P. Levesque

22 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mitchell P. Levesque Switzerland 10 198 86 62 49 48 26 325
Aimee L Leonard United States 8 169 0.9× 173 2.0× 79 1.3× 33 0.7× 84 1.8× 16 433
Aïda Ghoul France 8 254 1.3× 85 1.0× 44 0.7× 58 1.2× 41 0.9× 10 379
Cyril Maire France 7 103 0.5× 80 0.9× 33 0.5× 63 1.3× 67 1.4× 26 280
Yoshihiro Umebayashi Japan 10 241 1.2× 97 1.1× 34 0.5× 49 1.0× 66 1.4× 33 425
Sara Micaletto Switzerland 7 122 0.6× 237 2.8× 97 1.6× 19 0.4× 37 0.8× 11 469
Saima Usman United Kingdom 6 170 0.9× 108 1.3× 38 0.6× 82 1.7× 16 0.3× 9 343
Katrina Spaunhurst United States 5 199 1.0× 102 1.2× 25 0.4× 35 0.7× 101 2.1× 6 350
Shukai Yuan China 10 146 0.7× 124 1.4× 55 0.9× 97 2.0× 19 0.4× 16 372
Karen Jung Canada 12 220 1.1× 106 1.2× 42 0.7× 91 1.9× 14 0.3× 19 334
Bushra Al‐Ayadhy Kuwait 9 72 0.4× 100 1.2× 12 0.2× 46 0.9× 24 0.5× 14 278

Countries citing papers authored by Mitchell P. Levesque

Since Specialization
Citations

This map shows the geographic impact of Mitchell P. Levesque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell P. Levesque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell P. Levesque more than expected).

Fields of papers citing papers by Mitchell P. Levesque

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell P. Levesque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell P. Levesque. The network helps show where Mitchell P. Levesque may publish in the future.

Co-authorship network of co-authors of Mitchell P. Levesque

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell P. Levesque. A scholar is included among the top collaborators of Mitchell P. Levesque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell P. Levesque. Mitchell P. Levesque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morsy, Yasser, Patrick Turko, Marjam J. Barysch, et al.. (2025). The serum metabolome serves as a diagnostic biomarker and discriminates patients with melanoma from healthy individuals. Cell Reports Medicine. 6(8). 102283–102283.
2.
Rütsche, Dominic, Monica Nanni, Phil F. Cheng, et al.. (2025). Human Dermal Microvascular Arterial and Venous Blood Endothelial Cells and Their Use in Bioengineered Dermo‐Epidermal Skin Substitutes. Small Methods. 9(8). e2401588–e2401588. 1 indexed citations
3.
Esposito, Mauro, Zsolt Balázs, Evelyn Lattmann, et al.. (2024). COL10A1 expression distinguishes a subset of cancer-associated fibroblasts present in the stroma of high-risk basal cell carcinoma. British Journal of Dermatology. 191(5). 775–790. 3 indexed citations
4.
Cheng, Phil F., et al.. (2024). Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance. Cell Reports Medicine. 5(7). 101611–101611. 1 indexed citations
5.
6.
7.
Ostano, Paola, Soumitra Ghosh, Min Ma, et al.. (2023). Androgen receptor is a determinant of melanoma targeted drug resistance. Nature Communications. 14(1). 6498–6498. 22 indexed citations
8.
Amaral, Teresa, Oltin T. Pop, Tobias Sinnberg, et al.. (2023). EGFR expression and relapse in patients with melanoma receiving adjuvant PD-1-based immunotherapy.. Journal of Clinical Oncology. 41(16_suppl). e21566–e21566. 1 indexed citations
9.
Wietecha, Mateusz S., Michael Cangkrama, Andreas Goppelt, et al.. (2023). Phase-specific signatures of wound fibroblasts and matrix patterns define cancer-associated fibroblast subtypes. Matrix Biology. 119. 19–56. 8 indexed citations
10.
He, Yuliang, Jihye Kim, Carlotta Tacconi, et al.. (2022). Mediators of Capillary-to-Venule Conversion in the Chronic Inflammatory Skin Disease Psoriasis. Journal of Investigative Dermatology. 142(12). 3313–3326.e13. 10 indexed citations
11.
Bahri, Rajia, Ian Prise, Julia M. Martínez-Gómez, et al.. (2022). Human Melanoma-Associated Mast Cells Display a Distinct Transcriptional Signature Characterized by an Upregulation of the Complement Component 3 That Correlates With Poor Prognosis. Frontiers in Immunology. 13. 861545–861545. 14 indexed citations
12.
Tastanova, Aizhan, Muriel Elhaï, Kristina Bürki, et al.. (2022). An Optimized Tissue Dissociation Protocol for Single-Cell RNA Sequencing Analysis of Fresh and Cultured Human Skin Biopsies. Frontiers in Cell and Developmental Biology. 10. 872688–872688. 24 indexed citations
13.
Robotti, Francesco, Nadia Sanchez‐Macedo, Laura Frese, et al.. (2020). Lipoconstruct surface topography grating size influences vascularization onset in the dorsal skinfold chamber model. Acta Biomaterialia. 106. 136–144. 4 indexed citations
14.
Singer, Franziska, Anja Irmisch, Nora C. Toussaint, et al.. (2018). SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. BMC Medical Informatics and Decision Making. 18(1). 89–89. 12 indexed citations
15.
Freiberger, Sandra N., Phil F. Cheng, Piotr Dziunycz, et al.. (2015). Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. Molecular Cancer Therapeutics. 14(9). 2132–2142. 35 indexed citations
16.
Venturelli, Sascha, Tobias Sinnberg, Alexander Berger, et al.. (2014). Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells. Frontiers in Oncology. 4. 227–227. 35 indexed citations
17.
Cheng, Phil F., Jürg Hafner, A. Tschopp, et al.. (2014). Basal cell carcinomas in a tertiary referral centre: a systematic analysis. British Journal of Dermatology. 171(5). 1066–1072. 27 indexed citations
18.
Mangana, Joanna, Mitchell P. Levesque, Maria B. Karpova, & Reinhard Dummer. (2012). Sorafenib in melanoma. Expert Opinion on Investigational Drugs. 21(4). 557–568. 44 indexed citations
19.
Rozati, Sima, et al.. (2012). Real-life Experience With Pegylated Interferon and Conventional Interferon in Adjuvant Melanoma Therapy. Journal of Immunotherapy. 36(1). 52–56. 6 indexed citations
20.
Erlinger, Serge, et al.. (1969). Maladie de Rendu-Osler a localisation digestive. Diagnostic artériographique.. La Presse Médicale. 77(46). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aimee L Leonard Breakdown of academic impact, for papers by Aïda Ghoul Breakdown of academic impact, for papers by Cyril Maire Breakdown of academic impact, for papers by Yoshihiro Umebayashi Breakdown of academic impact, for papers by Sara Micaletto Breakdown of academic impact, for papers by Saima Usman Breakdown of academic impact, for papers by Katrina Spaunhurst Breakdown of academic impact, for papers by Shukai Yuan Breakdown of academic impact, for papers by Karen Jung Breakdown of academic impact, for papers by Bushra Al‐Ayadhy
Rankless by CCL
2026